🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GSK 257049

Found 17 matching trials

An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa

PHASE3

The purpose of this study is to conduct long-term surveillance for efficacy...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-18

Trial ID

NCT02207816

Treatments Being Tested

Blood sampling Malaria Vaccine 257049 (MALARIA-055 PRI)Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)Cell-culture rabies vaccine (MALARIA-055 PRI)TritanrixHepB/Hib (MALARIA-055 PRI)Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)

Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines

PHASE2

In this study, two experimental malaria vaccines (with adjuvants) are teste...

Status

Completed

Location

GSK Investigational Site

Start Date

2007-03-26

Trial ID

NCT00443131

Treatments Being Tested

GSK Malaria vaccine 257049

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.

PHASE1

GSK Biologicals is developing in partnership with the Malaria Vaccine Initi...

Status

Completed

Location

GSK Investigational Site

Start Date

2004-03-15

Trial ID

NCT00197067

Treatments Being Tested

RTS,S/AS02D and RTS,S/AS02A

Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

PHASE3

The purpose of this observer-blind study is to gather key efficacy, safety,...

Status

Completed

Location

GSK Investigational Site

Start Date

2009-03-27

Trial ID

NCT00866619

Treatments Being Tested

Malaria Vaccine 257049 Meningococcal C Conjugate Vaccine Cell-culture rabies vaccine TritanrixHepB/Hib Polio Sabin Oral Polio Vaccine (GSK)

Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

PHASE2

This study will evaluate whether administration of two investigational mala...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-08-10

Trial ID

NCT01366534

Treatments Being Tested

Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)GSK Biologicals' malaria vaccine 257049 (2 doses)GSK Biologicals' malaria vaccine 257049 (3 doses)Sporozoite challenge

Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen

PHASE2

This study is being done to assess the possibility of the potential integra...

Status

Completed

Location

GSK Investigational Site

Start Date

2007-04-30

Trial ID

NCT00436007

Treatments Being Tested

GSK 257049 Tritanrix™ HepB/Hib Rouvax™Stamaril™Polio Sabin™

Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children

PHASE2

GSK Biologicals is developing a number of candidate malaria vaccines for th...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-04-07

Trial ID

NCT00307021

Treatments Being Tested

GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049

Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.

PHASE2

This phase IIb trial is being done to find out if the RTS,S/AS01 vaccine he...

Status

Completed

Location

GSK Investigational Site

Start Date

2007-01-03

Trial ID

NCT00380393

Treatments Being Tested

GSK malaria vaccine 257049 Vaccine Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine

Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)

PHASE3

This study has been designed to support the indication of the candidate vac...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-11-17

Trial ID

NCT01345240

Treatments Being Tested

GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 Engerix-B™ vaccine Infanrix/Hib™ vaccine Polio Sabin™ vaccine Rotarix™ vaccine Synflorix™ vaccine Measles vaccine Yellow fever vaccine

Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants

PHASE2

GSK Biologicals in partnership with the Malaria Vaccine Initiative at PATH ...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-09-27

Trial ID

NCT00289185

Treatments Being Tested

RTS,S/AS02D Engerix-B®TETRActHib™

Previous Next